Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 4

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 4
---
kels, the lawful currency of the State of Israel, and the
terms “dollar,” “U.S. dollar” or “$” refer to United States dollars, the lawful currency of the United
States of America. All references to “shares” in this prospectus refer to Ordinary Shares of Regentis Biomaterials Ltd.,
no par value.

All share numbers in this
prospectus have been adjusted to give effect to a forward split of our outstanding Ordinary Shares, or the Split, at a ratio of 2.5 for
1, effected on March 20, 2025.

<div align='center'>TRADEMARKS</div>

Gelrin and GelrinC are trademarks
of ours that we use in this prospectus. This prospectus also includes trademarks, tradenames and service marks that are the property
of other organizations. Solely for convenience, our trademarks and tradenames referred to in this prospectus appear without the or ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent
under applicable law, our rights, or the right of the applicable licensor to our trademark and tradenames.

<div align='center'>MARKET, INDUSTRY AND OTHER DATA</div>

This prospectus contains
estimates, projections and other information concerning our industry, our business, and the markets for our product candidates. Information
that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties,
and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise
expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as
from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical
and general publications, government data and similar sources. None of the reports or studies cited in this prospectus were commissioned
by the Company.

In addition, assumptions
and estimates of our and our industry’s future performance are necessarily subject to a high degree of uncertainty and risk due
to a variety of factors, including those described in “Risk Factors.” These and other factors could cause our future performance
to differ materially from our assumptions and estimates. See “Special Note Regarding Forward-Looking Statements.”

<div align='center'>ii

PROSPECTUS SUMMARY</div>

This summary highlights selected information contained elsewhere in this